04Our VelocImmune technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companiesMany of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery systemProduct candidates in Phase 2 and Phase 3 clinical development include fianlimab, odronextamab, linvoseltamab, itepekimab, pozelimab + cemdisiran, and olatorepatide
data moatis wired into how the customer already works